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INTRODUCTION
Recombinant biological products have revolutionized modern medicine by providing both 
remarkably effective vaccines to prevent disease and therapeutic drugs to treat a wide variety 
of unmet medical needs. Since the early 1980s, dozens of new therapeutic protein drugs and 
macromolecular vaccines have been commercialized, which have benefitted millions of 
patients worldwide. The pharmaceutical development of these biological products presented 
many scientific and technical challenges, some of which continue today with newer 
candidates including recombinant protein-based vaccines with novel adjuvants, peptide and 
RNA-based drugs, and stem cellular therapies. Compared with small molecule drugs, the 
characterization, stabilization, formulation, and delivery of biomolecules share common 
hurdles as well as unique challenges. This area of drug development research has been 
referred to as “pharmaceutical biotechnology”, in recognition of the critical role that 
recombinant DNA technology plays in the design and production of most of these biological 
products. Current research focus areas in this field include (i) determination of structural 
integrity of the primary sequence, post-translational modifications, and higher-order three 
dimensional shapes, (ii) assessment of physicochemical degradation pathways and their 
effects on biological activity and potency, (iii) formulation design and development to 
optimize stability and delivery, (iv) evaluating and optimizing process development steps 
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including lyophilization and fill-finish, (v) analytical method development and applications 
of new instruments and data visualization tools, (vi) design and development of drug 
delivery approaches, and (vii) studies of biological effects including pharmacokinetics, 
pharmacodynamics, and adverse immunogenicity.
During the early days of pharmaceutical biotechnology research, there were numerous 
scientific challenges because the analytical characterization approaches needed for 
development of recombinant biological molecules in “real world” pharmaceutical dosage 
forms were essentially unknown. Furthermore, understanding critical drug product 
manufacturing issues (e.g., stability of biological compounds during processing, storage, and 
shipping as well as reproducibility of fill-finish production technologies) and behavior 
during and after patient administration was often achieved by “on-the-job” training. 
Fortunately, the pioneers in the field regularly presented research at key conferences and 
started publishing early in pharmaceutical sciences journals such as Journal of 
Pharmaceutical Sciences. Recognizing this critically important new field, the then Editor of 
the journal, Professor Bill Higuchi, instituted a new “pharmaceutical biotechnology” 
category for research papers. This insightful move was coupled with an equally wise 
decision to recruit Dr. C. Russell Middaugh as the new Associate Editor for the new research 
category. As will be detailed below, under Dr. Middaugh’s diligent and expert guidance, 
pharmaceutical biotechnology papers have grown in number, scope, and impact over the past 
20 years, and these days, the Journal of Pharmaceutical Sciences is viewed by scientific 
leaders in the field as the “go to” place for publication of the most important results and 
descriptions of innovations in pharmaceutical biotechnology.
TWENTY YEARS OF PHARMACEUTICAL BIOTECHNOLOGY IN JOURNAL 
OF PHARMACEUTICAL SCIENCES
The number of pharmaceutical biotechnology papers published in the Journal of 
Pharmaceutical Sciences from 1992 to 2013 is shown in Figure 1, both by year and 
cumulative number. These papers are categorized according to the pharmaceutical 
development of three different types of biotechnology-based product candidates: protein-
based therapeutics, other biological molecules (including peptides, polysaccharides, DNA/
RNA), and finally various macromolecular antigens (and adjuvants) being developed as 
vaccines. In 1994, Dr. C. Russell Middaugh joined the editorial board of Journal of 
Pharmaceutical Sciences as the first dedicated pharmaceutical biotechnology Editor. As can 
be seen in Figure 1, only a handful of biotechnology papers were published in 1993. From 
1994 to the present, under Professor Middaugh’s ongoing editorial guidance, approximately 
1000 pharmaceutical biotechnology papers have now appeared, with about half of the papers 
being published since 2007. For the first 6 months of 2014, 47 additional papers had been 
published (data not shown). This dramatic growth in pharmaceutical biotechnology papers in 
the Journal of Pharmaceutical Sciences parallels two major general trends in the 
biopharmaceutical industry over the past two decades: the emergence of therapeutic mAb 
drugs to address unmet medical needs for patients with a variety of disorders, especially 
cancer and autoimmune diseases, as well as the development of many new vaccines to 
protect both children and adults against a wide range of infectious diseases.
VOLKIN et al. Page 2













mAb DRUG APPROVALS OVER THE PAST TWENTY YEARS
To illustrate the tremendous growth in development of therapeutic mAb treatments over the 
past two decades, we focus on United States Food and Drug Administration (US FDA) 
approvals, although similar are trends would be observed with worldwide regulatory 
approvals. The first therapeutic mAb product approved for human use by the US FDA was 
Orthoclone OKT®3 in 1986; a mouse IgG2a antibody against the CD3 receptor on T-cells 
for treatment of acute rejection of organ transplants. For the following 8–10 years, it was 
unclear whether therapeutic mAbs would live up to their potential as “magic bullet” 
pharmaceutical treatments, and no additional full-length mAbs were approved. During this 
time period, however, great advances were achieved in the area of antibody engineering 
allowing for the humanization of mouse antibodies resulting in the ability to produce 
chimeric, humanized, and fully human mAbs (approximately 75%, 95%, and 100% human 
amino acid sequences, respectively).1 As shown in Figure 2, in 1994, the second mAb-based 
product was approved by the US FDA, a chimeric antibody fragment (anti-glycoproteinIIb/
IIIa Fab) used as a platelet aggregation inhibitor (ReoPro®). Starting in 1997 to the present, 
approximately 30–35 new therapeutic mAbs have been approved for commercial use with 
one to four new mAb approvals per year (except for no US FDA approvals in 1999 and 
2005).2–5 When examining the overall trend over the past 20 years, mAbs have grown and 
evolved into the major category of protein-based therapeutics, and this trend is expected to 
continue as newer technologies such as antibody–drug conjugates, bispecific antibodies, and 
various types of antibody-based fragments and fusion proteins become available as 
therapeutic molecules.
Approximately two-thirds of the therapeutic mAbs on the market are administered by 
intravenous (i.v.) injection, with most of the other mAb treatments injected subcutaneously, 
along with a few other administration routes including intramuscular and intravitreal (based 
on a review of online package inserts). In terms of pharmaceutical dosage forms, mAbs have 
been formulated as either liquid solutions (~2/3 of total) or freeze-dried powders (~1/3 of 
total) (based on a review of online package inserts). Liquid mAb formulations are filled and 
packaged into either glass vials or prefilled syringes (PFS), the latter can be used with auto-
injectors as mAb drug-device combination products. Both pharmaceutical dosage forms and 
related administration procedures for therapeutic mAb treatments have become more 
sophisticated over the past 20 years. For example, in 1998 the first approved anti-tumor 
necrosis factor alpha (anti-TNF) mAb treatment, Remicade® produced by Centocor (now 
part of J&J), consists of a chimeric mAb which is lyophilized at 100 mg/vial, reconstituted 
with 10 mL sterile water for injection, and administered i.v. by medical professionals. In 
2009, the same company introduced a newer anti-TNF mAb treatment (Simponi®) as a fully 
human mAb, formulated as a 100 mg/mL high concentration aqueous solution. A patient-
convenient dosage form was utilized with the liquid formulation filled into a PFS, which in 
turn, is placed into an auto-injector allowing for self-administration at home/doctor’s office 
via subcutaneous (SC) injection.6
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NEW VACCINE APPROVALS OVER THE PAST TWENTY YEARS
The past 20 years have also witnessed a surge in development and commercialization of new 
vaccines, both in terms of new vaccine antigens and new formulations and delivery 
technologies. As shown in Table 1, there has been an impressive and diverse array of 
macromolecules and microorganisms developed as new vaccines including polysaccharide-
protein conjugates (e.g., pneumococcal and meningococcal vaccines), killed and live, 
attenuated viruses (e.g., hepatitis A, rotavirus and shingles vaccines) as well as recombinant 
protein technologies including virus-like particles (human papillomavirus or HPV vaccine) 
and a recombinant hemagglutinin flu vaccine.7 In addition, new formulations and delivery 
technologies have been introduced to improve and expand the utility of vaccines such as 
influenza (e.g., nasal and intradermal delivery, new adjuvants). Finally, new formulations 
containing mixtures of older, already approved vaccines have also been developed to 
decrease the complexity of the vaccination schedule and better ensure compliance (e.g., 
measles, mumps, rubella and varicella; and, although not listed in Table 1, diphtheria, 
tetanus toxoid, acellular pertussis, hepatitis B and inactivated poliovirus vaccines).
From a pharmaceutical dosage form perspective, live attenuated viral vaccines tend to be 
lyophilized and do not require adjuvants. This can be attributed to the inherent complexity 
and instability of microorganisms along with their ability to replicate upon administration 
and thus better mimic a natural infection. One exception in the 1993–2013 time period is the 
successful development of a liquid formulation of the orally administered rotavirus vaccine, 
which required identification of stabilizers to ensure stability of a pentavalent virus mixture 
when stored at 2–8°C in a plastic squeeze tube, and at the same time, provide sufficient acid 
neutralizing capacity to protect the viruses from gastric acid degradation during oral 
administration.8
Another trend to note in Table 1 is that inactivated viral and subunit vaccines (e.g., 
polysaccharide-protein conjugates, recombinant protein virus-like particle vaccines) tend to 
be formulated as liquid solutions containing adjuvants to enhance their immunogenicity. 
Aluminum salts have been used as adjuvants for decades, and most new vaccines still 
contain this conventional adjuvant. It is interesting to note that despite decades of research to 
identify and develop new adjuvants, US FDA approvals have occurred only relatively 
recently including GSK produced HPV vaccine with AS04 (aluminum adjuvant and 
monophosphoryl lipid A) in 2009, and a biodefense flu vaccine in the US stockpile with 
AS03 (emulsion containing squalene, polysorbate 80 and DL-alpha-tocopherol) in 2013. 
Additional vaccine formulations containing new adjuvants have been approved by European 
regulatory agencies including oil-in-water emulsions as adjuvants for flu vaccines (not 
shown). One interesting pharmaceutical biotechnology-related case study for new protein-
based vaccines is the stabilization and formulation of the human papillomavirus virus-like 
particles (HPV VLPs). When the recombinant viral surface protein was recombinantly 
expressed in yeast and then assembled into virus-like particles in vivo, the purified VLPs 
were observed to form a mixture of fully and partially assembled particles. An in vitro large 
scale disassembly and reassembly procedure was developed and implemented to ensure the 
formation of correctly assembled virus-like particles, resulting in enhanced potency and 
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improved stability (accelerated and long-term storage) for a quadrivalent, aluminum 
adsorbed HPV VLP vaccine formulation.9
DEVELOPMENT TRENDS OVER THE PAST 20 YEARS IN 
PHARMACEUTICAL BIOTECHNOLOGY
Physicochemical Stability of Protein Drugs
After three decades of diligent research, pharmaceutical scientists now know that the safety 
and efficacy of therapeutic protein drug products can be compromised not only via post-
translational modifications in the cell, but also by well-defined physical and chemical 
degradation pathways. It has also become apparent that sometimes even trace amounts of 
modified or degraded protein can result in suboptimal to adverse effects in patients (see 
immunogenicity section below). We have learned that proteins can be extremely susceptible 
to such degradation and that such damage can occur at all stages of a protein product’s life 
history, from fermentation, purification, formulation/storage to patient administration (and 
perhaps in vivo within the patient). Furthermore, the starting bulk drug substance can 
contain a wide range of molecular variants, e.g., subpopulations with different glycosylation 
patterns or charged isoforms, which can have different pharmaceutical properties such as 
receptor binding, pharmacokinetic profiles and propensity to aggregate.
Physical Stability—Currently, the study of protein physical stability is understood to 
encompass characterization of degradation products such as “soluble” aggregates (e.g., 
oligomers), “particles” (submicron, subvisible and visible) and larger precipitates. In 
addition, a particular concern for low dose drug products is the loss of potency due to 
adsorption of protein molecules to the container/closure (e.g., wall of glass vials or rubber 
stopper) and/or the delivery system (e.g., bags for i.v. administration). In addition, physical 
stability can refer to the key properties of the native protein under various solution 
conditions; e.g., the effects of pH or ionic strength on a protein’s conformational and 
colloidal stability. In turn, it is now better understood that these physical properties can 
govern the rates of degradation of a given protein (e.g., aggregation rate). Furthermore, 
pharmaceutically unacceptable physical properties can include opalescent appearing 
solutions, liquid-liquid phase separation and high solution viscosity. These properties are 
particularly problematic with the development of high concentration (e.g., 100–200 mg/ml) 
formulations of mAbs.
Moreover, it has been well established that there are exposures to numerous stresses during a 
protein product’s life history that readily induce aggregation, particle formation and/or loss 
of protein molecules from solution due to adsorption at interfaces. These include freeze-
thawing, exposure to extremes of pH, filtration steps, pumping during fill-finish and fluid 
transfers, exposure to various surfaces and interfaces in primary containers and delivery 
systems, as well as agitation and other stresses during shipping. Many of the stresses result 
in exposure of protein molecules to interfaces to which they can adsorb, resulting in 
assembled networks of native and/or structurally altered protein molecules on the interface. 
Disruption of the assembled films or gels formed at the interfaces (e.g., during agitation) can 
result in protein aggregates or particles in the bulk solution. In addition, extrinsic, foreign 
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particles can be shed from essentially any material to which protein solutions are exposed, 
(e.g., silicone oil-in-water, stainless steel particles-in-water, glass delamination) and protein 
molecules can readily adsorb to the foreign particle-liquid interfaces resulting in 
heterogeneous particle formation. These may, in turn, stimulate further protein aggregation 
and particle formation, especially upon exposure to pharmaceutically relevant stresses (e.g., 
freeze-thawing or agitation).
In concert with the efforts to delineate the causes of protein physical degradation, 
tremendous progress has been made in understanding mechanisms by which proteins can be 
stabilized against such damage and in developing effective means to minimize degradation. 
This work includes both theoretical and experimental advances, which have led to much 
more rationale design of protein stabilizers, high-throughput formulation development 
approaches to optimize protein formulation composition, and to more powerful data 
processing/data visualization methods. Also, approaches to reduce the detrimental impact of 
processing conditions have been studied at lab scale, and resulting mitigation strategies have 
been scaled-up and implemented in commercial manufacturing settings.
Thirty years ago the field was not aware of many of the numerous problems that can arise 
during the scale-up, manufacturing and shipping/handling of therapeutic proteins, because 
the development efforts for these products were in their infancy. Through rigorous and 
insightful research over the intervening years, and the publication of important results and 
theoretical insights, pharmaceutical biotechnology has made remarkable progress. Many of 
the key papers have been (and continue to be) published in Journal of Pharmaceutical 
Sciences. These publications include impactful Commentaries and Reviews, as well as 
numerous seminal research papers. For example, over the years, higher resolution, more 
sensitive and increasing reliable characterization and quantitation assays for monitoring 
protein aggregation and particle formation have been developed. This progress in developing 
improved analytical tools has greatly increased our insights into how protein physical 
degradation can readily occur and our understanding that if even minute fractions of a 
protein product become degraded, there may be detrimental impacts on subsequent protein 
stability and product quality, and on product safety and efficacy in patients (as discussed in 
more detail below).
Chemical Stability—Since the inception of development of therapeutic proteins, in 
parallel with research efforts to understand and control protein physical stability, intensive 
research also has been focused on the chemical stability of proteins, which is also critically 
important for safety and efficacy of therapeutic protein products. Decades of advancements 
in the field were required to develop the theoretical and practical understanding – and the 
requisite advances in analytical capabilities – that we now have about chemical degradation 
of therapeutic proteins. There are many different pathways for chemical degradation that 
have been elucidated in extensive mechanistic detail including oxidation, deamidation, and 
hydrolysis of certain amino acid residues. This in turn has led to a better understanding of 
chemical hotspots in protein molecules (e.g., Asn deamidation, Asp isomerization, Met 
oxidation, and Trp photo-degradation). In addition to chemical degradation, chemical 
heterogeneity in therapeutic protein products is also well-established, for example, disulfide 
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isoforms, charged variants, C-terminal lysine and N-terminal pyroglutamate variants, and 
even proteolytic clippings.
Early efforts often focused on investigations of causes and control of known chemical 
degradation pathways and discovery of new pathways. It was quickly realized that 
conditions encountered during processing, storage, shipping, and delivery could lead to rapid 
chemical degradation of specific amino acid residues and/or the polypeptide backbone. 
These conditions included exposures to: metals from processing equipment, primary 
containers and/or excipients; peroxides from surfactants; extremes of pH; and light. Current 
control strategies now include screening of excipient lots for metals and peroxides, and the 
replacement of stainless steel processing equipment with single-use plastic systems. But the 
plastic systems have not been without problems, for example, substances leaching from the 
plastics have been found in some cases to cause chemical degradation of therapeutic 
proteins. For some products, despite these efforts, chemical degradation is so extensive in 
solution that freeze-drying is required to ensure chemical stability and a multi-year shelf life.
Light exposure during manufacturing is minimized with approaches such as running a side 
stream from a chromatography system through the UV detector while the main flow is not 
exposed to light. In addition, using secondary packaging helps to reduce light exposure in 
the final product container. But there are still unintended and poorly controlled situations in 
which light exposure and potential damage can occur to the protein product. For example, 
when patients are warming a PFS prior to administration at home, they may place it on the 
kitchen counter in direct sunlight. Similarly, during preparation and administration of i.v. 
products, there is exposure to room lights and potentially to sunlight. Such exposures can 
cause substantial photochemical (and physical) degradation of proteins.
There also has been much effort on developing formulation approaches to minimize 
chemical damage to proteins in the drug substance and in the final formulated drug product. 
Some successful approaches that have been implemented include the selection of the optimal 
solution pH and the inclusion of free radical scavengers (e.g., methionine) and/or metal ion 
chelators in the formulation. It has also been discovered that other additives, such as the 
pharmaceutical anti-oxidant ascorbate, may actually accelerate protein chemical degradation 
by catalyzing the generation of free radicals in solution under certain conditions. In other 
cases, inclusion of appropriate excipients has been documented to inhibit light-induced 
degradation in some proteins, whereas in other studies they have been found to be ineffective 
for another protein. The difference might be due to the locations of the damage-sensitive 
amino acid residues within the protein molecule. For example, residues located on the 
protein surface may be protected to some degree by stabilizing excipients in the solution, 
whereas residues that are degraded because of photon absorption in the interior of the 
protein may not be protected by components in the formulation.
Chemical damage and physical stability are often linked. For example, oxidation of amino 
acid residues within a protein may also lead to protein aggregation, perhaps including 
covalent crosslinks. Another example is creation of a protein species with reduced solubility 
via fragmentation or proteolytic clipping of the polypeptide backbone, leading to protein 
precipitation. Conversely, perturbation of the tertiary structure of a protein molecule may 
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result in more rapid degradation of amino acid residues that were previously buried in the 
most compact species in the native state ensemble. The exact nature of such linkages 
between chemical and physical stability cannot be predicted – nor can the consequences of 
the damage. Consequently, Arrhenius kinetics cannot be relied on to give accurate 
predictions of degradation rates or shelf life, adding complexity to formulation development 
for biologics compared to small molecules. Careful studies are needed to characterize the 
degradation profile for each given protein and to develop formulations to minimize both 
physical and chemical degradation pathways. Often times, a compromise is required to 
identify conditions that lead to optimal overall protein stability, conditions which in turn, 
may not be optimal for every individual physical or chemical degradation pathway.
As has been the case for publications on physical stability of therapeutic proteins, many of 
the key research papers, Reviews and Commentaries have been, and continue to be, 
published on the topic of chemical stability of protein drug candidates in Journal of 
Pharmaceutical Sciences. These papers are further evidence of the important roles that the 
journal has played in the advancement of the field for the past two decades.
Immunogenicity of Biotech Drugs
For millions of patients, therapeutic protein products are miracle drugs that save and 
improve lives. However, for many patient populations these miracle drugs, which are 
initially highly effective, eventually fail in a fraction of the initial responders. Depending on 
the product and patient group, the fraction of these so-called “secondary non-responders” 
may reach 50% or higher, with many patients developing treatment failure in less than a year 
or two. In some cases, (e.g., rheumatoid arthritis patients treated with anti-TNF therapies) 
patients can be switched to another product in the same class with a restoration of 
therapeutic effectiveness. But even these patients may experience subsequent treatment 
failures. For other patients there is no alternative therapy or they have already used all of the 
approved biologics. In these cases, they suffer from loss of treatment with the protein 
miracle drugs, resulting in morbidity or even death.
It is now widely documented that treatment failure is usually due to adverse immunogenicity 
caused by the protein drug product. Since the 1960s, many clinical investigations and animal 
studies have shown that a major contributing factor to immunogenicity is the presence of 
protein aggregates and particles. Even trace amounts of these degradation products can 
stimulate an immune response leading to generation of antibodies that neutralize the drug’s 
activity and/or promote its rapid clearance from the body. Furthermore, immune response to 
aggregates and particles can be greatly enhanced if the protein molecules are absorbed onto 
pharmaceutically relevant foreign particles (e.g., glass from vials or stainless steel from 
filling pumps) and/or are chemically degraded (e.g., oxidized). Therefore, major research 
efforts are now devoted to understanding and controlling the levels of such protein 
aggregates, particles and chemically degraded species. Concurrently regulatory expectations 
in this area are becoming increasingly more stringent. As with the other categories 
considered in this Commentary, many of the most innovative and influential research papers, 
Reviews and Commentaries in the area of immunogenicity of protein drugs, its causes, 
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mechanisms and related regulatory expectations have been published in the Journal of 
Pharmaceutical Sciences.
Pharmaceutical Dosage Forms
In the 1980s and early 1990s, some of the new therapeutic protein products were being 
developed in traditional “small molecule” pharmaceutical companies. Often there was a 
philosophical, as well as a physical separation of biotechnology R&D/production from small 
molecule pharmaceutical R&D/production. These organizational silos not only led to 
differences in the education and training of scientists and managers, but to differences in 
overall management approaches. At the same time, some of the new protein therapeutics 
were being developed in stand-alone biotechnology companies. Often the protein 
biochemists and molecular biologists had completely different trainings and experiences 
than the drug development experts who were brought into the new biotech companies from 
traditional pharmaceutical companies. For example, biotechnology researchers often worked 
in systems that operated relatively freely and had an attitude toward research and 
development more akin to that which they experienced in academic universities. In contrast, 
the traditional pharmaceutical scientists and process development experts were focused on 
implementation of current good manufacturing practices (cGMP), reducing time to market, 
and commercial scale-up and distribution.
Overall, new thinking and interfacing was needed in both the start-up biotechnology and 
traditional pharmaceutical companies to successfully develop protein drugs. With 
therapeutic proteins, the starting point for drug product formulation was not a dry, crystalline 
powder but a “bulk solution”. The term “preformulation of proteins” is sometimes used to 
refer to the activities related to developing a bulk protein solution into a well characterized 
pharmaceutical dosage form with a “drug product history” including frozen and thawed, 
heated for viral deactivation, pH adjusted, dialyzed, diluted and reformulated, as well as 
sterile filtered, filled into final containers, and in some cases lyophilized.
Approaches to protein drug product development have changed dramatically over the last 
25–30 years. Many companies have been successful in managing the interface between 
biotechnology R&D and more traditional pharmaceutical product development approaches, 
although some companies still struggle with this challenge. Also, in many cases, the gaps 
between drug substance and final drug product formulation have vanished, and bulk protein 
solutions are developed such that they are provided ready to fill. In addition, formulation 
work has been shifted towards earlier phases of R&D, including the selection of the final 
protein molecule candidate, via an early evaluation of physicochemical properties and 
product stability (i.e., “developability” or “drugability” assessments). The early paradigm of 
drug selection followed by formulation studies that must somehow find a way to stabilize the 
molecule has largely been abandoned and replaced by a more integrated approach, at least in 
the hands of more experienced biologics therapeutics developers. This approach is widely 
used, for example, with mAb products for which several high-affinity candidate molecules 
may be developed for a given target, followed by a selection process to identify the 
candidate with the best pharmaceutical properties of stability, solubility and 
manufacturability. In some cases, compatibility of the candidate molecules with the final 
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anticipated primary containers/closures (e.g., PFSs) may be assessed early as part of the 
candidate selection screening process.
The vast majority of protein drugs require parenteral delivery and therefore sterile 
packaging. The rise of the therapeutic protein products is correlated with the decline of the 
ampule, the classical primary container often used in parenteral delivery. When the first 
protein products came out in the late 1980s and into the 1990s, certain standard 
pharmaceutical glass vials and stoppers were the dominant, or in some cases, the only 
choice. From a practical standpoint they could be used for both aqueous solution and 
lyophilized formulations. Little innovation in glassware occurred in the first years, but there 
were important improvements in the rubber stoppers. For example, stoppers coated with 
polytetrafluoroethylene and similar materials came to the market to minimize leachable 
compounds that could affect protein stability. Although these new stoppers were slow to be 
adopted by the industry primarily because of the relatively high price, today these coated 
stoppers are widely used.
Another trend in the choice of primary packaging, which represented new thinking in drug 
delivery and self-administration of therapeutic proteins, was the increased use of “ready to 
use” prefilled syringes (PFSs). In the 1990s, the change to a PFS container was typically 
only implemented as a life-cycle management strategy and only for the most commercially 
successful products. Today, PFSs are considered standard primary packaging for many 
therapeutic protein product candidates. PFSs are now produced in the hundreds of millions 
units annually. The widely available “nested” pre-sterilized syringes in closed trays now 
make it possible to operate exactly the same configuration for filling and packaging from the 
first 100-piece developmental batch up to large-scale commercial manufacturing. With these 
products in hand, millions of patients today self-inject their life changing medications at 
home. On the basis of these improvements in PFS technology, autoinjectors have been 
brought to the customer too, making self-injection even more convenient.
A major development challenge in the switch of a therapeutic protein product from a glass 
vial to a PFS (or even when a PFS is the first container/closure option investigated) is that a 
formulation that may have worked well in terms of maintaining protein stability in a glass 
vial may not provide adequate stability in a PFS. This effect is usually because of the 
destabilization of protein molecules that can occur upon adsorption to the silicone oil that is 
used for plunger lubrication. Furthermore, the combination of protein adsorption to the oil–
water interface and exposure to the air–water interface that can occur in PFS has been shown 
to promote protein aggregation and particle formation. However, with a combination of 
mechanistic and practical studies, rational formulation strategies have been devised for 
developing stable aqueous solution protein formulations in PFSs. Descriptions of many of 
the key studies in this area have also been published as Research Papers and Reviews in 
Journal of Pharmaceutical Sciences.
Although there is much interest in needle-free injection (NFI), NFI is still not readily 
available for parenteral administration of protein drugs. Barriers to NFI adoption include 
relatively higher costs, lack of bioequivalency compared with regular subcutaneous injection 
via a needle, and finally, experience demonstrating that “needle-free” is not necessarily 
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“pain-free”. Nevertheless, because needle stick injuries are a global problem and reuse of 
syringe and needles is a serious issue in some countries, evaluation of NFI technologies will 
undoubtedly continue for both currently available therapeutic protein and vaccine products 
and for new clinical candidates.
Development of stable dosage forms to ensure long term storage has always been a 
challenge and is critically important for commercialization of biotechnology-based drugs 
and vaccines. In an effort to meet this challenge, lyophilization has become a successful 
alternative to provide the required stability in commercial formulations. There have been 
several interesting trends in this field over the last 20 years. Firstly, for the fundamental 
scientific studies in the 1980s and 1990s began to elucidate the mechanisms by which 
certain excipients stabilize a protein during freezing, drying, storage in the solid state, and 
finally, upon reconstitution. At the same time, empirical studies in industry screened for 
effective excipients that were practically useful; that is, compounds that stabilized proteins 
which were also used in approved parenteral products and could be lyophilized relatively 
economically on a commercial scale. With the groundbreaking work of academic and 
industry researchers around the globe, there is now a solid understanding of how to 
rationally select excipients and process parameters for successful lyophilization of a protein 
drug. Furthermore, the essential analytical methods to monitor protein stability—such as 
solid-state differential scanning calorimetry (DSC) and IR spectroscopy—and the associated 
physical properties that govern structural integrity of a lyophilized cake, have now been well 
established. Also, advances in process control and freeze-drying cycle development 
approaches have resulted in more economical, robust, and consistent commercial scale 
manufacturing of lyophilized protein formulations.
Over the past 20 years and continuing to today, many critical Research Papers and Reviews 
on mechanisms for protein stabilization during lyophilization and subsequent storage in the 
freeze-dried state in various formulations have been published in Journal of Pharmaceutical 
Sciences. In parallel, several key papers on new analytical methods and process 
development/control strategies have appeared in the journal, and it is still a leading venue for 
publication in this field. There are many new challenges in development of lyophilized 
formulations, including those for ultra-high concentration mAb products and dual 
chambered syringes, and there will be many more groundbreaking studies in the field. The 
Journal of Pharmaceutical Sciences will continue to be an important repository for the 
Research Papers describing this new work and for Reviews summarizing the key advances.
Novel Drug Delivery Approaches
It is interesting to note that during the first ~10 years of Pharmaceutical Biotechnology 
papers being published in the Journal of Pharmaceutical Sciences (1994–2004), only about 4 
biomolecules reached over $1 billion annual sales.10 For the second ~10 years, the increased 
rate in pharmaceutical biotechnology manuscripts being published in Journal of 
Pharmaceutical Sciences (Fig. 1) coincided with the rapid growth in commercially available 
mAb therapeutics (Fig. 2). This growth in therapeutic biomolecule approvals, combined with 
investments by small, medium and large pharmaceutical sponsors, has been reflected in the 
annual sales of biotherapeutic products. For example, many of the anti-TNF antibody 
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products have reached annual sales exceeding $6 billion, and have become top income 
producer of major pharmaceutical companies.11 Although mAbs are administered to patients 
by injections, there is a growing interest in how protein pharmaceutics could potentially be 
made more effective, safer and convenient for patients through novel drug delivery 
technologies. As patient compliance and therapeutic adherence are issues central to the 
overall outcomes clinical care, scientists across disciplines are taking integrated drug 
delivery approaches to address these issues.
The overarching goal of drug delivery is to improve the therapeutic index by enhancing 
safety and/or efficacy, or to improve convenience—and preferably both. The field 
encompasses a very broad range of technologies, from device innovations such as portability 
and biofeedback regulation (e.g., insulin delivery devices linked to glucose sensors that 
monitor insulin effects in patient) to platforms such as colloid, micro, and nano drug carriers 
or particles which require knowledge of physiologic mechanisms in biopharmaceutics as 
well as the pharmacokinetic characteristics of the drug (which can include proteins and 
peptide as well as most of the DNA/RNA or nucleic acid-based biologicals). By one 
estimate, the annual revenue of drug delivery products, including biotechnology-based and 
small molecule drugs, is over $57 billion and is projected to have an annual growth rate of 
5%–10%.11 Advances in protein, peptide and DNA/RNA research, combined with clinical 
experience using these biopharmaceuticals as therapeutics, have provided key information 
on distinctive disposition characteristics, the role of protein sequence variations, details of 
the barrier dynamics to protein absorption, and to some degree, drug target distribution in 
the body as it relates to drug effects. The growing knowledge of these properties, 
collectively referred to as biopharmaceutical characteristics and pharmacokinetic profiles as 
they are linked to therapeutic responses, has allowed for further development of novel drug 
delivery strategies. Many of these discoveries, development and drug delivery technologies 
are documented in Journal of Pharmaceutical Sciences, enabling scientists across disciplines 
and around the world to gain access to the vast knowledge in drug delivery research in 
academic and pharmaceutical industry.
These drug delivery strategies, placed in the context of human physiological interactions—
referred to as a “systems approach” to drug delivery—can be categorized as control release, 
permeation enhancement, modulation of drug clearance, targeting to the site of action, as 
well as molecular optimization. However, these delivery systems remain very challenging to 
develop for biologics. For example a polymeric sustained release formulations of 
recombinant human growth hormone (rhGH) (Nutropin Depot) was approved by the US 
FDA and marketed for several years. However, a variety of manufacturing and delivery 
challenges were encountered with this dosage form leading to a decision by the sponsor to 
discontinue production of this product.12 Despite the challenges, development of sustained 
release dosage forms for biologics continues and has led more recently to the 2012 approval 
and commercialization of Bydureon®, a sustained release formulation of a 39 amino acid 
peptide, glucagon-like peptide-1 (GLP-1) agonist.
The clinical impact of drug delivery systems may be viewed in the context of how a 
particular approach improves the therapeutic index, for example by dose reduction or 
through minimizing untoward effects after extended dosing. The best results are often 
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achieved with drug localization strategies that enhance exposure to target tissues and cells 
but reduce drug exposure in organs linked to toxicity. The biodistribution of all drug targets 
in cells and tissues within the body is yet to be fully understood. However, virus- or bacteria-
laden cell distribution, and by extension their protein target localization in cells and tissues, 
are now mapped, elucidated, and validated for defined organs within the body. Some of the 
recent efforts in developing and validating pharmacokinetic relationship with therapeutic 
outcomes or pharmacodynamics as well as pharmacometrics definitions would add to these 
knowledge base to guide dose selection and the type of drug delivery strategies to maximize 
therapeutic effects. Such knowledge has led to successful development of targeted drug 
delivery systems to improve the therapeutic index. Research to discover sites of drug action 
through proteomic modeling and high-throughput screening has yielded targets that have 
been used to construct fusion proteins with added effector function to enhance 
pharmacologic activity. The efficiency of identifying drug targets has improved and cloning 
technology has matured. Through a systems approach, pharmaceutical formulation and 
effective delivery to the target cells and tissues central to potentiating therapeutic effects 
have become one the key rate-limiting steps for bringing new molecular entities to market.
Although the development of gene- and cell-based medicine has been slow, it continues to 
mature. Although gene therapy intended for cancer treatment and enzyme replacement may 
be a distance away, the use of DNA-based vaccines, and more recently RNA-based vaccines, 
is on the horizon. Nucleic acids, which are polar and poor cell penetrants, often face 
challenges in reaching the intracellular targets after injection treatment in animal models and 
in human clinical trials. A number of nucleic acid delivery systems, including lipid- or 
protein-based technologies as well as viral or vector-based technologies, also pose 
significant challenges in terms of off-target cellular and tissue distribution (e.g., liver) and/or 
a low degree of functional impact within the target cells. Thus, even with the exciting work 
with siRNA and RNAi for a number of target therapeutic genes in vitro and in animal 
models, the inability to deliver a sufficient fraction of these agents into target cells has 
prompted a scale back in clinical development programs within major pharmaceutical 
companies, although efforts continue in dedicated start-ups and other settings. Although 
low-volume cell-based therapeutics, including stem cell and immune cell therapeutics 
currently in clinical trials for skin and other cancers, are promising, they are still in the 
clinical research stage. These highly publicized stem-cell therapeutics—in vitro or in situ—
will likely mature with time.
There is now substantial and cumulative clinical experience using different classes of protein 
molecules—mAb, enzymes, interferons, cytokines, hematopoietic growth and coagulation 
factors, hormone and peptides, vaccines, and nucleic acid (including aptamers)—that can be 
applied to development of biopharmaceuticals. This knowledge has given insight to the 
strengths and weaknesses in localization, distribution, and pharmacokinetics, as well as 
disposition and elimination pathways for specific biomolecule classes. Leveraging this 
knowledge, drug delivery systems are being developed to improve safety while enhancing 
effectiveness through better localization and exposure to target cells and tissues.
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Advances in Analytical Methods
The primary structure or amino acid sequence of a therapeutic protein drug, along with any 
post-translational modifications produced by a recombinant expression system, has to be 
confirmed and monitored. Around two decades ago, this could be a very difficult task 
experimentally. However new tools, especially mass spectrometry, have emerged as key 
analytical techniques for the determination of the primary structure of a therapeutic protein. 
In particular, mass spectrometry combined with HPLC (LC–MS) has dramatically changed 
the reliability, sensitivity, and speed of sequence analysis.
Before mass spectrometry, confirmation of primary structure could be achieved by the 
combination of results from different analytical methods. The full amino acid composition 
of the protein was determined by amino acid analysis. The amino acid sequence of the 
protein and/or of peptides fragmented by single or multiple enzymatic treatments of the 
protein were assessed mainly by N-terminal sequence analysis using the Edman degradation 
method. Advancements of mass spectrometers and related methods over the past two 
decades, especially highly improved resolution of mass determination, has enabled us to 
more directly analyze proteins and peptide fragments. Molecular mass of the protein without 
enzymatic digestion can be estimated by mass spectrometry with high accuracy. In most 
cases, electron spray ionization or matrix assisted laser desorption ionization is used for the 
ionization, followed by mass measurement via quadrupole, ion-trap, time-of-flight, or 
Fourier transform mass spectrometer, and/or a combination of these approaches. Typically, 
more than 95% of the total sequence is covered by mass spectrometry of enzymatically 
digested peptides. Patterns of disulfide bonding are also determined by mass spectrometry of 
digested protein under non-reducing conditions. Today, even trace amounts of degraded 
protein can be correctly analyzed by mass spectrometry, as can the inherent post-
translational heterogeneity of a therapeutic protein drug such as the glycosylation pattern.
Capillary electrophoresis also is now a standard method, often replacing traditional 
polyacrylamide gels, to estimate molecular weight of a protein and to quantify levels of 
disulfide cross-linked aggregates. Moreover, two decades ago, net charge variations of 
proteins were characterized by ion exchange chromatography and/or isoelectric focusing 
electrophoresis using immobilized pH gradient gels. Today, charge heterogeneity properties 
of protein drugs are routinely analyzed by capillary electrophoresis approaches including 
capillary IEF (cIEF). This approach provides higher resolution results in a relatively short 
time.
Several methods have been used in protein biochemistry to study the higher order structures 
of proteins. X-ray crystal structure analysis has long history in the determination of protein 
three-dimensional structure at high resolution. In addition, for more than 20 years nuclear 
magnetic resonance analysis has been applied to the high resolution structure analysis of 
proteins in solution. However, these methods require elaborate work up, and remain 
relatively complicated techniques requiring specialized and costly equipment, highly skilled 
researchers, and considerable expenditure of time. Thus, these methods, although useful for 
research applications, are not used on a routine basis, especially in pharmaceutical dosage 
forms containing a variety of excipients.
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Instead, for therapeutic proteins, lower resolution methods have been used for higher-order 
structural characterization and comparisons. For example, circular dichroism (CD) 
measurement has been used for the secondary structure (far-UV range) and for tertiary 
structure (near-UV range) of the proteins. Non-linear regression analysis of the far-UV CD 
spectrum provides contents of secondary structure. Intrinsic fluorescence of a tryptophan 
residue reflects the local environment of the residue, and thus fluorescence measurements 
have been used to monitor changes in the tertiary structure of proteins. These methods can 
also be interfaced with automated temperature controlled cuvette holders, allowing for 
determination of the thermal stability of the secondary and tertiary structure of proteins, 
often a useful surrogate for examining higher-order structural integrity of proteins. To this 
end, DSC can provide thermodynamic parameters of protein stability directly and has used 
for this purpose in basic protein research for the past two decades. Improved sensitivity, 
reproducibility and throughput of calorimeters now enable its use for the assessment of 
relative thermal stability of therapeutic proteins, an approach that is valuable in product 
characterization, comparability studies and formulation screening. Hydrogen deuterium 
exchange mass spectrometry (HDX-MS), the most recently emerging technique for higher 
order structure analysis, has been used in a growing number of studies of therapeutic 
proteins in recent years. HDX-MS can provide site specific higher-order structural 
information at several amino acid residues resolution, which is difficult to acquire by other 
analytical methods, especially in the presence of the excipients that are often required to 
stabilize therapeutic protein drugs.
In addition to monitoring the structural integrity and conformational stability of therapeutic 
proteins, analysis of hydrodynamic properties such as overall size and shape of the molecule 
is important, especially as related to monitoring protein aggregation. Several analytical 
approaches are commonly used including size-exclusion chromatography (SEC) as well as 
dynamic and static light scattering. Analytical ultracentrifugation has been also been widely 
used for quaternary structure studies and native-state self-assembly, as well as for 
characterization and quantitation aggregates due to physical degradation. As discussed 
below, these aggregates can form larger assemblies, often referred to as particles, which can 
raise regulatory concerns.
As in the case of other research areas discussed in this Commentary, many seminal Research 
Papers, Reviews, and Commentaries on protein structural analysis have been and continue to 
be published in Journal of Pharmaceutical Sciences. The strength of the journal in this 
important area of pharmaceutical biotechnology is evidenced not only by the many high 
quality papers from this field, but also the numerous members of the Editorial Advisory and 
Scientific Advisory Boards of Journal of Pharmaceutical Sciences who are leaders in areas 
of protein biophysical chemistry and its application to therapeutic protein characterization.
Regulatory Expectations
Along with the many scientific advances in pharmaceutical biotechnology made over the 
past two decades, regulatory expectations for product quality and appropriate analytical 
methods have increased substantially. Often, there has been an iterative process by which a 
group of researchers makes critical advances in an area and publish their work, which then 
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triggers the regulatory authorities to begin asking for these new advances to be employed by 
sponsors. The Journal of Pharmaceutical Sciences has played a key role in not only 
publishing the latest scientific findings and reviews in pharmaceutical biotechnology, but 
also as a forum for highlighting and debating these emerging topics “in real time” via the 
journal’s commentary section.
For example, in the early days of the field until today, SEC has been the method of choice 
for characterization and quantitation of protein aggregates. A group of researchers with 
academic training in protein native state self-assembly began using analytical 
ultracentrifugation as a complementary method to study aggregation in therapeutic protein 
products. They quickly realized that results with SEC often did not accurately reflect the 
actual aggregate levels and types in a protein product. They then created research approaches 
that used AUC during SEC method development to assure that the latter method was 
accurate and provided proper results. Because much of this work was published, including 
commentaries in Journal of Pharmaceutical Sciences,13 regulators at agencies such as the US 
FDA soon came to expect that this approach to monitor protein aggregation be used for 
during development of most (if not all) therapeutic protein products.
More recently, it has been recognized that there was an “analytical gap” in studies of protein 
physical degradation because subvisible particles smaller than 10 micron were not being 
routinely studied and characterized for therapeutic protein products. This became a topic of 
several commentaries in Journal of Pharmaceutical Sciences.14,15 Based on instrument 
advances and calls from regulators to “fill this gap,” the field is now routinely quantifying 
and characterizing micron and submicron sized particles in therapeutic protein products. 
Today control strategies for protein degradation in manufacturing, storage, shipping, and 
delivery now include a focus on subvisible particles. These examples highlight the important 
role that research papers, reviews and commentaries published in Journal of Pharmaceutical 
Sciences can play in elucidating the nature, and debating the current status, of critical 
product quality issues affecting protein drugs. The journal continues to be the choice for 
industry, regulatory agencies, and academia alike to publish new insights and calls for 
improvements in assessment of product quality affecting clinical safety and efficacy.
CONCLUDING REMARKS
The purpose of this commentary is not only to reflect on the scientific and technical 
advances that have occurred in pharmaceutical biotechnology over the past 20 years, but to 
illustrate the key role played by Journal of Pharmaceutical Sciences in presenting and 
debating these achievements. As shown in Figure 1, approximately 1000 pharmaceutical 
biotechnology papers have appeared in the past 20 years in the Journal of Pharmaceutical 
Sciences under the leadership of the Biotechnology Editor, Professor C. Russell Middaugh. 
As highlighted by the guest editors, many specific pharmaceutical biotechnology 
development issues have been researched, and in many cases now successfully addressed, 
for protein, peptide and nucleic acid-based drug and vaccine candidates under development: 
elucidation of physicochemical mechanisms of instability, development and scale-up of 
pharmaceutical dosage forms, challenges in novel drug delivery challenges, and the key role 
of analytical characterization and developing new analytical approaches.
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What does the next 20 years have in store for pharmaceutical biotechnology? As highlighted 
in Figure 2 and Table 1, essentially an entire new class of protein drugs (therapeutic mAbs) 
and many new and important vaccines were developed and approved for human use over the 
past 20 years. What new class of biotechnology products will account for the new therapies 
and vaccines in the next 20 years? What pharmaceutical development challenges will 
emerge to develop, manufacture and commercialize them to successfully address today’s 
unmet medical needs? Although we can only guess at possible answers to such questions, 
we do know with certainty we can look forward to the next 1000 pharmaceutical 
biotechnology papers in Journal of Pharmaceutical Sciences to find out!
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The number of pharmaceutical biotechnology papers published in the Journal of 
Pharmaceutical Sciences from 1993 to 2013. Data are shown by year (left axis, bar chart) 
and cumulative number (right axis, black circle). Dr. C. Russell Middaugh joined the 
editorial board as the dedicated editor for biotechnology papers in January 1994 and 
continues in that role to the present. Papers covering different aspects of pharmaceutical 
biotechnology including development of protein-based therapeutics, other biological 
molecules as drug candidates (peptides, polysaccharides, DNA/RNA), and vaccine 
candidates (macromolecular antigens and adjuvants) are indicated by color in the bar charts. 
Data were collected from review of table of contents from 252 issues of the journal from 
1993 to 2013.
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The number of therapeutic mAbs approved by the US FDA from 1993 to 2013. Data are 
shown by year (left axis, bar chart) and cumulative number (right axis, red squares) (2–5). In 
1993, only one therapeutic mAb drug had been approved for commercial use versus 35 mAb 
therapeutics in 2013 (see text).
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